AIMS: To determine the systemic thrombogenic effect of radiofrequency catheter isolation of the pulmonary veins (PVI) in the treatment of atrial fibrillation. METHODS AND RESULTS: We studied endothelial damage marker (von Willebrand factor [vWf]), fibrinolysis markers (tissue plasminogen activator [t-PA], plasminogen activator inhibitor-1 [PAI-1]) and coagulation activation markers (D-dimer [DD]) in 30 patients (pts) undergoing PVI. Heparin was administered continuously after double transseptal puncture in all pts. Concentrations of vWf and t-PA were significantly increased after accomplishing PVI compared to the baseline values, and elevated levels persisted 24 hours later ( p < 0.01). PAI-1 levels decreased following PVI compared to the baseline levels ( p = 0.02). PAI-1 levels normalized 24 hours after the procedure. DD increased continuously during the procedure with the peak following PVI ( p < 0.01). Higher DD concentrations persisted 24 hours later ( p = 0.02). In a multivariate analysis, total procedure time correlated significantly with the peak vWf and DD concentrations, while total RF energy dose correlated only with peak vWf ( r = 0.82). Time to heparin administration correlated with DD levels prior to the first RF pulse ( r = 0.83, p < 0.01) as well as after PVI ( r = 0.75, p < 0.01). A group of patients heparinized within the first hour of the PVI procedure had normal preablation DD levels and significantly mitigated DD levels following PVI compared to the group of patients heparinized later ( p < 0.01). CONCLUSIONS: Pulmonary vein ablations cause an increased systemic procoagulant state as reflected by fibrin turnover, fibrinolysis activation and endothelial perturbation. The activation of the coagulation cascade could be decreased by early heparin administration.

1 Department of Medicine University Hospital Olomouc Czech Republic

See more in PubMed

Circulation. 1998 Nov 24;98(21):2241-7 PubMed

Baillieres Clin Haematol. 1995 Jun;8(2):313-27 PubMed

Am J Cardiol. 1997 Feb 15;79(4):494-7 PubMed

Blood Coagul Fibrinolysis. 1993 Dec;4(6):1007-21 PubMed

J Am Coll Cardiol. 1996 Nov 1;28(5):1257-61 PubMed

Jpn Circ J. 1994 Feb;58(2):123-35 PubMed

Thromb Haemost. 1999 Sep;82 Suppl 1:14-8 PubMed

Am Heart J. 1989 Dec;118(6):1317-23 PubMed

Am J Cardiol. 1996 Mar 15;77(8):655-8 PubMed

Adv Exp Med Biol. 1997;425:131-41 PubMed

Pacing Clin Electrophysiol. 2001 Jan;24(1):5-12 PubMed

Br Heart J. 1995 Jun;73(6):527-33 PubMed

Br J Biomed Sci. 1993 Jun;50(2):125-34 PubMed

Pacing Clin Electrophysiol. 1995 Nov;18(11):1980-90 PubMed

J Cardiovasc Electrophysiol. 1999 Apr;10(4):611-20 PubMed

Circ J. 2002 Jul;66(7):671-6 PubMed

J Cardiovasc Electrophysiol. 1999 Apr;10(4):503-12 PubMed

Pacing Clin Electrophysiol. 1991 Nov;14 (11 Pt 2):1992-7 PubMed

Eur Heart J. 1993 Dec;14(12):1644-53 PubMed

Vnitr Lek. 2004 Apr;50(4):305-11 PubMed

Thromb Haemost. 1999 Aug;82(2):576-84 PubMed

Europace. 2001 Jul;3(3):195-200 PubMed

J Cardiovasc Electrophysiol. 1998 Nov;9(11):1144-51 PubMed

Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1359-62 PubMed

Pacing Clin Electrophysiol. 1994 Oct;17(10):1610-20 PubMed

Cardiovasc Res. 1997 May;34(2):255-65 PubMed

Chest. 1993 Nov;104(5):1455-60 PubMed

Stroke. 2000 Jan;31(1):26-32 PubMed

Respiration. 2002;69(6):526-33 PubMed

Blood. 1999 Jul 1;94(1):179-85 PubMed

Can J Cardiol. 1994 Oct;10(8):835-9 PubMed

Thromb Haemost. 2001 Jul;86(1):366-73 PubMed

J Cardiovasc Electrophysiol. 1998 Nov;9(11):1152-60 PubMed

Thromb Haemost. 2001 Jul;86(1):164-71 PubMed

Am Heart J. 1999 Jul;138(1 Pt 1):128-32 PubMed